We are grateful to Drs Nguyen, Mularz, and Valderramos for their interest in our study and their concerns regarding the power of our study. The sample size was calculated assuming a 15% rate of perinatal death (fetal death and neonatal death ≤28 days) in the prompt delivery group, a 2-sided α error of 5%, and 80% power to detect a reduction of 30% in the rate of perinatal death with the expectant management. Statistical analysis was performed with the help of a statistician and with Epi software number 7 from the Centers for Disease Control. The assumption of 15% perinatal mortality rate for those delivered promptly came from the study by Odendaal et al that had higher neonatal deaths in the prompt delivery group and reflects the reality of the countries involved in our study. We agreed that this trial was under-powered to detect a difference in perinatal death between prompt deliveries vs expectant management groups, because under the conditions of this study the perinatal death was only 9.4% in the prompt delivery group. The lower perinatal mortality rate seen in the study was probably due to the uniformed use of antenatal steroids in all patients who were delivered promptly, and the decreased rate of neonatal death was attributed to this intervention. However, this trial had double the number of randomized patients compared with 2 previous studies combined. Until further randomized studies are performed, we conclude that, in developing countries, expectant management of severe preeclampsia after treatment with corticosteroids and <34 weeks’ gestation does not result in neonatal benefit and can result in greater risk for abruption and small for gestational age.